公开(公告)号：US11492628B2

公开(公告)日：2022-11-08

申请号：US15763709

申请日：2016-10-05

申请人： BioNTech SE ,  TRON—Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg-Universität Mainz gGmbH

发明人： Alexandra Orlandini Von Niessen ,  Stephanie Fesser ,  Britta Vallazza ,  Tim Beissert ,  Andreas Kuhn ,  Ugur Sahin ,  Marco Alexander Poleganov

IPC分类号： C12N15/67 ,  A47B3/00 ,  A47B13/02 ,  A47B33/00 ,  A47B43/00 ,  A47B77/02 ,  A47B77/06 ,  A47B77/08 ,  A47B77/16 ,  A47B77/18 ,  A47B95/00 ,  A47C4/00 ,  A47C4/08 ,  A47C7/00 ,  A47K3/28 ,  B60B33/00 ,  E04H1/12 ,  F16C11/04 ,  C12N5/0735 ,  C12N15/113 ,  C12N15/90

摘要： The present invention relates to stabilization of RNA, in particular mRNA, and an increase in mRNA translation. The present invention particularly relates to a modification of RNA, in particular in vitro-transcribed RNA, resulting in increased transcript stability and/or translation efficiency. According to the invention, it was demonstrated that certain sequences in the 3′-untranslated region (UTR) of an RNA molecule improve stability and translation efficiency.

公开(公告)号：US20230272406A1

公开(公告)日：2023-08-31

申请号：US17936377

申请日：2022-09-28

申请人： BioNTech SE ,  TRON-Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg-Universität Mainz gG

发明人： Alexandra Orlandini Von Niessen ,  Stephanie Fesser ,  Britta Vallazza ,  Tim Beissert ,  Andreas Kuhn ,  Ugur Sahin ,  Marco Alexander Poleganov

IPC分类号： C12N15/67 ,  A47B3/00 ,  A47B13/02 ,  A47B33/00 ,  A47B43/00 ,  A47B77/02 ,  A47B77/06 ,  A47B77/08 ,  A47B77/16 ,  A47B77/18 ,  A47B95/00 ,  A47C4/00 ,  A47C4/08 ,  A47C7/00 ,  A47K3/28 ,  B60B33/00 ,  E04H1/12 ,  F16C11/04 ,  C12N5/0735 ,  C12N15/113 ,  C12N15/90

CPC分类号： C12N15/67 ,  A47B3/002 ,  A47B13/02 ,  A47B33/00 ,  A47B43/00 ,  A47B77/022 ,  A47B77/06 ,  A47B77/08 ,  A47B77/16 ,  A47B77/18 ,  A47B95/00 ,  A47B95/008 ,  A47C4/00 ,  A47C4/08 ,  A47C7/002 ,  A47C7/006 ,  A47K3/284 ,  B60B33/00 ,  E04H1/1266 ,  F16C11/04 ,  C12N5/0606 ,  C12N15/113 ,  C12N15/90 ,  A47B2003/006 ,  A47B2200/0018 ,  C12N2310/113

摘要： The present invention relates to stabilization of RNA, in particular mRNA, and an increase in mRNA translation. The present invention particularly relates to a modification of RNA, in particular in vitro-transcribed RNA, resulting in increased transcript stability and/or translation efficiency. According to the invention, it was demonstrated that certain sequences in the 3′-untranslated region (UTR) of an RNA molecule improve stability and translation efficiency.

公开(公告)号：US20230265454A1

公开(公告)日：2023-08-24

申请号：US18007550

申请日：2021-06-01

申请人： BioNTech SE ,  TRON - Translationale Onkologie an der Universitätsmedizin der Johannes Gutenber-Universitä Mainz

发明人： Mario Perkovic ,  Sonja Witzel ,  Tim Beissert ,  Ugur Sahin

IPC分类号： C12N15/86 ,  C12N15/113

CPC分类号： C12N15/86 ,  C12N15/113 ,  C12N2770/36143

摘要： The present invention embraces an RNA replicon (self-amplifying RNA vector (saRNA)) that can be replicated by a replicase of a self-replicating virus, e.g., a replicase of alphavirus origin. According to the invention, translation of the replicase open reading frame is uncoupled from a 5′-terminal cap by placing translation of the replicase open reading frame under the translational control of an internal ribosome entry site (IRES). Thereby the initiation of translation depends on the molecular properties of the respective IRES, which compared to cap-dependent translation may require less or no cellular initiation factors to direct the ribosome to the translational start site. According to the invention, IRES-controlled replicase translation may allow the use of uncapped synthetic saRNA. Furthermore, the use of an IRES provides for the option to insert additional transgenes upstream to the IRES.